
Assessing Biosecurity Concerns Related to Synthetic Biology

Update by the NSABB Working Group on Synthetic Genomics

David Relman, WG Chair




Topics



- Charge to WG
- Roundtable on Synthetic Biology
- Overview of Synthetic Biology
- Working Group Preliminary Findings
- Working Group Preliminary Recommendations

WG Charge




 Identify any biosecurity or dual use concerns that may be associated with synthetic biology and that would not be adequately addressed by the dual use research oversight framework proposed by the NSABB

Working Group Members

- David Relman (Chair)
- Susan Ehrlich
- Claire Fraser-Liggett
- John Gordon
- Mike Imperiale
- Adel Mahmoud
- Harvey Rubin
- Tom Shenk

- Ken Cole (DoD)
- Dan Drell (DoE)
- Jose Fernandez (DHHS)
- Maria Giovanni (NIH)
- Wendy Hall (DHS)
- Sue Haseltine (DoI)
- Caird Rexroad (USDA)
- Jenifer Smith (FBI)
- Scott Steele (EOP/OSTP)
- Ron Walters (Intelligence)
- Rob Weyant (CDC)




- October 2007
- Hosted by:
 - NSABB WG on Synthetic Genomics
 - NIH RAC Biosafety WG (addressing an NSABB recommendation accepted by USG)

• To explore:

- State of the science in "synthetic biology"
- Current capabilities for predicting function
- Risk assessment and risk management in a context of uncertainty

- Session I: State of the Science
- Speakers
 - Roger Brent
 Director and President
 Molecular Sciences Institute, Berkeley, CA
 - Steven Benner
 Distinguished Fellow
 Foundation for Applied Molecular Evolution, Gainesville, FL
 - Ron Weiss
 Professor of Electrical Engineering
 Princeton University
 - Steen Rasmussen
 Team Leader for Self-Organizing Systems
 Los Alamos National Laboratory




Questions to Speakers


- How they define "synthetic biology", what makes it unique from other scientific approaches;
- Goals and experimental approaches in synthetic biology;
- Current capabilities and applications associated with synthetic biology;
- How these capabilities go beyond what is achievable using recombinant DNA or other related technologies;
- Major milestones to date in synthetic biology and the current challenges;
- Future directions and goals;
- How close we are to predicting the detailed behavior of a cell based on its component parts;
- How close we are to designing biological systems and novel organisms with predictable functions; and
- Whether their synthetic biology research routinely undergoes biosafety review.

- Session II: Predicting Function
- Speakers:
 - Bill Goldman
 Professor of Molecular Microbiology
 Washington U School of Medicine
 - Jim Musser
 Co-Director and Executive VP
 Methodist Hospital Research Institute
 - Marc Kirschner
 Chair, Systems Biology
 Harvard Medical School
 - Owen White


Director of Bioinformatics, Institute for Genome Sciences U Maryland School of Medicine



- Questions to Speakers
 - How accurately can virulence or other pathogenic properties be predicted on the basis of sequence alone? Can the predictions be generalized;
 - What kinds of genes/sequences are sufficient for establishing virulence in a heterologous, avirulent organism;
 - What factors determine the evolutionary distance across which virulence might be genetically transferred? Does current understanding of lateral gene transfer help us predict the degree to which virulence can be manipulated or created de novo;
 - Major challenges and unmet needs that hinder recognition and prediction of virulence;
 - Considerations for predicting function within systems;
 - What properties of an organism are most successfully predicted from genetic sequence;
 - Degree to which current knowledge allows construction of entirely new organisms with predictable behaviors;
 - Capabilities, limitations, current uses of tools or approaches for predicting function from sequence.




- Session III: Risk Assessment and Risk Management in a Context of Uncertainty
- Panelists:
 - Rocco Casagrande
 Managing Director
 Gryphon Scientific
 - Larry McCray
 Research Associate, Emerging Technologies
 MIT




Discussion Questions

- Are there novel or distinct biosafety risks or challenges associated with "synthetic biology"?
- To what degree are the biosafety risks of synthetic biology currently being addressed?
- For recombinant DNA research, the initial risk assessment is based on properties of the parental organism. For the more novel synthetic organisms, a parental organism may not be obvious and/or the biological properties of the new organism may be largely unknown. How to approach risk assessment and management in such cases?
- Can one engineer biological containment into synthetic systems/organisms (e.g, use of unnatural genetic code or amino acids, self-destruct mechanisms, other safeguards)?
- Are there any existing risk assessment tools that would be applicable to the biosafety risk assessment process in the context of synthetic biology?



From: Elowitz, Leibler; Nature 403:335, 2000

What is Synthetic Biology?



- Life, altered by humans
- Novel functionalities
- Unnatural components
- Natural parts, unnatural assembly
- Artificial systems that mimic properties of natural organisms; allow quantitative predictions of behavior
- Approach: emphasis on design and testing via simulation, before fabrication, design-based biological engineering
- Goal: predictive biological understanding

What is Synthetic Biology?



- Many definitions, uses, stated goals--no clear consensus
- For the purposes of the WG, "Synthetic Biology" refers to the design and construction of novel organisms (viruses, microbes, plants, animals, etc) with predictable properties—with varying degrees of reliance on a master "blueprint" from Nature. It encompasses:
 - Design of novel biological "circuits" and components, and construction of organisms (both free-living and dependent) based on properties of components; as well as
 - Re-design and synthesis of existing, natural organisms for specific purposes

What is Synthetic Biology? Approaches



- Design and synthesis of a new organism with predictable properties using basic functional (genetic) components ("building blocks")..."Bottom-up approach"
- Design and/or synthesis starting with an extant organism or blueprint..."Top-down approach"
 - "the re-design of existing, natural biological systems for specific purposes" [syntheticbiology.org]
 - Synthetic genomics
- Blends of the two
- Degree to which entire genome is synthetic varies...


Working Group Deliberations




- What are the biosecurity/DURC risks associated with synthetic biology?
- Are these risks novel as compared to those identified for synthetic genomics or rDNA?
- Are the biosecurity risks adequately addressed by the oversight framework for dual use research recommended by the NSABB or are additional measures necessary?
- If additional biosecurity measures are warranted, what should they be?



- Multiplicity of definitions, goals, and approaches in synthetic biology
- Recurring theme:
 - There remain significant limitations to our current ability to custom design novel organisms with defined properties, such as pathogens, in a predictable manner, either by de novo synthesis or by re-engineering extant organisms



- The practice of synthetic biology presupposes an ability to predict biological properties from sequence or structure.
- Biological function exists at many levels (genetic sequence, molecular structure, cellular physiology, organ histology). It continues to elude efforts at formal derivation.
- Further work, experimental and theoretical, is needed (and can be expected) for improved predictive capabilities



- Risk assessment is problematic and difficult, especially for organisms that share few similarities with extant organisms.
- In light of this uncertainty, it is important to conduct synthetic biology research under appropriate biosafety conditions




- Biosafety risks presented by synthetic biology may not be recognized by all practitioners
 - Despite the term synthetic biology, not all practitioners consider that their work is biological in nature. Many think of themselves as engineers or chemists and so they may not be considering the biological and public health implications of their work.
 - In addition, many practitioners have backgrounds that are not rooted in the life sciences. Consequently, their training may not have included or emphasized principles and practices of biological risk assessment and biocontainment.
- Raising awareness within the disparate scientific communities that engage in synthetic biology about the possible biosafety risks and need for responsible conduct of research is critical. The biosafety outreach and education effort must recognize that the synthetic biology community is not confined to the life sciences.




- The biosecurity or dual use research risks associated with synthetic biology should be considered on the basis of experimental aim and approach.
 - Bottom-up" approach, without reliance on an extant organism, is still in its infancy, and does not pose any significant biosecurity or dual use research concerns at the present time that would not be addressed by the proposed oversight system. However, this work is advancing quickly and deserves re-visiting at regular intervals.



- The design, construction, and use of new biological parts, devices, and systems ("top-down" approach) is a well-developed and ongoing endeavor. Reengineering of extant organisms or viruses using methods in molecular biology is well-established. This work may be considered dual use research of concern, but it should also be adequately addressed by the oversight paradigm previously proposed by the NSABB.
- With all of these approaches, the science and technology is evolving quickly. It behooves us to revisit both the biosecurity and the biosafety issues on a regular basis.




- As synthetic biology techniques become easier and less expensive, the range of practitioners will continue to expand to include not only scientists and engineers, but hobbyists.
- It is unlikely that traditional research/biosafety oversight practices will adequately address the less traditional users.




- The increasing dissemination of synthetic biology technology creates challenges for education and oversight.
 - Clearly, students at all levels need to be educated about the importance of working safely and responsibly. At the same time, we must be mindful to avoid the unintended effects of stifling opportunities and excitement about science among students.
 - Education efforts and biosafety oversight requirements need to be tailored to the audience.




- The goals, potential benefits and risks, and current limitations of synthetic biology are not uniformly understood within the scientific community and the general public.
 - More effective and extensive dialogue within and across the disparate scientific communities engaged in synthetic biology would be useful in this regard, especially regarding the need to address biosafety in the conduct of synthetic biology research.
 - More effective outreach to the general public would foster a more realistic understanding of synthetic biology and its goals and current limitations.




- The proposed system of oversight for dual use research of concern should be adequate for addressing the potential for deliberate misuse of synthetic biology, at the present time
 - No current need for special biosecurity oversight of synthetic biology




- Synthetic biology should be subject to institutional biosafety review and oversight
 - Once the NIH completes the development of biosafety guidance for synthetic biology, the USG should launch a biosafety outreach and education program targeted to the research communities that are most likely to undertake work under the umbrella of synthetic biology
 - Focus should be raising awareness about the potential biological, dual use, and public health implications of their work, as well as the need for considering and addressing any biosafety risks during the conduct of the research



- Extend the oversight of dual use research of concern beyond the boundaries of the life sciences
 - Synthetic biology is just one example of an area of science that may pose some dual use concerns and whose practitioners are trained in multiple disparate scientific disciplines
 - Research that is highly relevant to the life sciences or that has implications for public health is currently, and will increasingly, be conducted outside of the life sciences



- Oversight of dual use research of concern should be uniform and comprehensive; extend the oversight of dual use research of concern beyond federally funded research
 - Dual use research of concern is as likely to be conducted in the private and voluntary sectors as it is in federal labs and in federally funded labs in academia



- USG should include advances in synthetic biology and mechanisms of virulence or pathogenicity, in "tech-watch" or "sciencewatch" endeavors
 - The USG should convene workshops to assess or reassess the biosecurity implications of work in synthetic biology and other fields that enhance our ability to engineer new virulence capabilities in organisms. It will be important to assess whether new research avenues and technologies are adequately addressed by the extant biosecurity/dual use research oversight system.